SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved.
Data readout from Phase 3 clinical trial in the People s Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial.
Gyre Therapeutics, Inc.: Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.